Ceftriaxone for Injection — Competitive Intelligence Brief

Ceftriaxone for Injection (Ceftriaxone for Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Third-generation cephalosporin. Area: Infectious Disease.

marketed Third-generation cephalosporin Penicillin-binding proteins (PBPs) Infectious Disease Small molecule

Target snapshot

Ceftriaxone for Injection (Ceftriaxone for Injection) — The University of Queensland. Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ceftriaxone for Injection TARGET	Ceftriaxone for Injection	The University of Queensland	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)
Fortaz	Ceftazidime	Pai Holdings Pharm	marketed	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Comparison 1: Prehospital Ceftriaxone	Comparison 1: Prehospital Ceftriaxone	Dr. Damon Scales	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)
Cefdinir (drug)	Cefdinir (drug)	University of Chicago	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)
azithromycin and cefixime	azithromycin and cefixime	Sheba Medical Center	marketed	Combination antibiotic (macrolide + third-generation cephalosporin)	Bacterial 50S ribosome (azithromycin); bacterial cell wall peptidoglycan (cefixime)
Cefotaxime/ceftriaxone	Cefotaxime/ceftriaxone	Centre Hospitalier Universitaire de Besancon	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)
Ceftriaxone v penicillin and gentamicin	Ceftriaxone v penicillin and gentamicin	Kamuzu University of Health Sciences	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Third-generation cephalosporin class)

1. Abbott · 1 drug in this class
2. Centre Hospitalier Universitaire de Besancon · 1 drug in this class
3. Dr. Damon Scales · 1 drug in this class
4. Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · 1 drug in this class
5. Kamuzu University of Health Sciences · 1 drug in this class
6. Korea United Pharm. Inc. · 1 drug in this class
7. Merck Sharp & Dohme LLC · 1 drug in this class
8. Murdoch Childrens Research Institute · 1 drug in this class
9. Pai Holdings Pharm · 1 drug in this class
10. RESnTEC, Institute of Research · 1 drug in this class